VANCOUVER, British Columbia, April 02, 2024--Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study. This achievement marks a significant milestone in the journey to bring this groundbreaking technology to patients in the United States, with

Related Keywords

Vancouver , British Columbia , Canada , United States , Montreal , Quebec , New York , United Kingdom , British , Kevin Chaplin , Stefan Avall , Vivek Reddy , Kardium Inc , Mcgill University Health Centre , Drug Administration , Investigational Device Exemption , Pre Market Approval , Globe System , Mount Sinai Hospital , Atul Verma , Globe Catheter ,